Key Highlights
- RLMD shares climbed approximately 31% during Monday’s pre-market session following two significant company announcements
- Phase 2 interim results for NDV-01 in bladder cancer patients demonstrated a 76% complete response rate at 12 months
- Relmada closed an oversubscribed private investment of $160 million at $4.75 per share
- The financing deal comprises 29.47 million shares plus pre-funded warrants for 4.21 million additional shares, with closing scheduled for March 11
- Analysts maintain a Strong Buy rating on RLMD stock with a consensus target price of $10.25
The company released interim results from its Phase 2 clinical study evaluating NDV-01 in patients with high-risk non-muscle invasive bladder cancer (NMIBC). The data revealed an impressive 76% complete response rate at the 12-month mark, accompanied by a well-tolerated safety profile. Notably, this response threshold was also achieved among BCG-unresponsive patients.
According to Dr. Raj S. Pruthi, MD, who serves as Relmada’s Chief Medical Officer of Oncology, the findings represent “meaningful clinical validation” for the development program.
Relmada Therapeutics, Inc., RLMD
Relmada announced plans to progress NDV-01 into a pivotal Phase 3 registration program known as RESCUE, which will pursue two distinct patient populations: those with BCG-unresponsive disease and intermediate-risk patients receiving adjuvant therapy. The Phase 3 trial launch is targeted for mid-2026.
Private Placement Details
In conjunction with the clinical update, Relmada disclosed the pricing of an oversubscribed private placement totaling $160 million.
The financing structure includes 29,474,569 shares of common stock priced at $4.75 per share, alongside pre-funded warrants covering 4,210,527 additional shares at $4.749 with an exercise price of just $0.001.
The transaction is being facilitated by Jefferies, Leerink Partners, Piper Sandler, and Mizuho serving as placement agents. Closing is anticipated for March 11, 2026, pending satisfaction of customary closing conditions.
Funds raised will support general working capital needs and fuel ongoing research and development initiatives across the company’s pipeline.
The investment agreement grants resale registration rights to participating investors. Relmada has agreed to meet specific SEC filing timelines, with potential liquidated damages of 1.0% for each 30-day delay period, though these penalties are subject to maximum caps.
Share Price Activity
RLMD climbed 31.01% during Monday’s pre-market hours. The stock had recorded a modest gain in Friday’s regular session.
For the year-to-date period, shares remain down 7.87%. Looking at the trailing 12-month performance, the stock has delivered remarkable gains of 1,536%.
Trading activity spiked dramatically with Monday’s news. Volume exceeded 7.9 million shares, far surpassing the three-month average daily turnover of approximately 570,000 shares.
This volume spike — representing more than 13 times normal levels — underscores the significant market interest generated by the dual announcements.
Analyst sentiment on RLMD currently stands at Strong Buy, reflecting four Buy recommendations published in the last three months.
The consensus price target among analysts is $10.25, implying potential upside of roughly 130% from present trading levels.
